Community-acquired pneumonia (CAP), one of the common infectious diseases, exhibits increasing morbidity and mortality with age, posing significant clinical challenges. Although Chinese patent medicines (CPMs) demonstrate efficacy in adult CAP treatment, high-quality evidence-based guidelines have been lacking. To address this gap, we organized a multidisciplinary expert panel to develop the Guideline on Treating Community-acquired Pneumonia with Chinese Patent Medicines, adhering to the principles of evidence-based, consensus-supplemented, and experience-referred and following standardized clinical practice guideline development procedures. Through literature review and Delphi questionnaires, six clinical questions were identified. Systematic evidence retrieval and synthesis of the best available evidence were conducted, integrating factors such as evidence quality, patient preferences, value orientations, and resource allocation. After two rounds of Delphi surveys and expert consensus meetings, the guideline was finalized and published in 2023 in Pharmacological Research. This updated edition systematically incorporates recent evidence, adds pharmacoeconomic evaluations and recommendation rationales, and presents 14 recommendations covering nine CPMs, covers 9 kinds of traditional Chinese patent medicines. The guideline has been restructured according to the first edition of reporting checklist for Chinese patent medicine guidelines (RIGHT for CPM) to enhance clinical applicability, accessibility, and operationalizability, thereby promoting the rational use of CPMs in adult CAP treatment.

社区获得性肺炎（CAP）是常见的感染性疾病之一，其发病率和病死率随年龄增长而上升，当前治疗面临诸多挑战。中成药治疗成人CAP疗效明确，但缺乏高质量循证指南。为此，课题组组织多学科专家，遵循"循证为主、共识为辅、经验为鉴"原则，参照临床实践指南研制规范，通过文献调研、德尔菲法问卷遴选出6个临床问题，系统检索并整合当前最佳循证证据。在综合评估证据质量、患者意愿、价值取向及资源配置等因素的基础上，通过两轮德尔菲调研及专家共识会议，最终形成《中成药治疗成人社区获得性肺炎临床应用指南（2022版）》，于2023年发表在Pharmacological Research。本次修订对证据进行了系统更新，新增药物经济性及推荐理由，共形成14条推荐意见，涵盖9种中成药，并依据首部中成药临床实践指南报告规范完成改编，以提升指南临床适用性、可及性及可操作性，促进中成药在成人CAP治疗中的合理使用。